The antithrombotic effects of CI-1031 (ZK-807834) and enoxaparin in a canine electrolytic injury model of arterial and venous thrombosis

Author： McClanahan T.B.   Hicks G.W.   Morrison A.L.   Peng Y.-W.   Janiczek-Dolphin N.   Mertz T.E.   Sullivan M.E.   Morser J.   Juneau P.L.   Leadley R.  

Publisher： Elsevier

ISSN： 0014-2999

Source： European Journal of Pharmacology, Vol.432, Iss.2, 2001-12, pp. : 187-194

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Discovery of the Factor Xa Inhibitor, ZK 807834 (CI-1031)

By  

Current Topics in Medicinal Chemistry, Vol. 1, Iss. 2, 2001-06 ,pp. : 121-136

Bentham Science Publishers

Access to resources Recommend Favorite

Antithrombotic effects in a rat model of aspirin-insensitive arterial thrombosis of desethyl KBT-3022, the main active metabolite of a new antiplatelet agent, KBT-3022

By Shimazawa M.   Takiguchi Y.   Umemura K.   Kondo K.   Nakashima M.  

European Journal of Pharmacology, Vol. 328, Iss. 2, 1997-09 ,pp. : 183-189

Elsevier

Access to resources Recommend Favorite

Enoxaparin/eptifibatide vs heparin/eptifibatide: antithrombotic effects

By  

Inpharma, Vol. 1, Iss. 1430, 2004-01 ,pp. : 20-20

Adis International

Access to resources Recommend Favorite

Antithrombotic activity of AT-1015, a potent 5-HT 2A receptor antagonist, in rat arterial thrombosis model and its effect on bleeding time

By Kihara H.   Koganei H.   Hirose K.   Yamamoto H.   Yoshimoto R.  

European Journal of Pharmacology, Vol. 433, Iss. 2, 2001-12 ,pp. : 157-162

Elsevier

Access to resources Recommend Favorite

Future therapies for the prevention and treatment of venous and arterial thrombosis

By McKean M-L.   Adelman S.J.  

Expert Opinion on Investigational Drugs, Vol. 7, Iss. 5, 1998-05 ,pp. : 687-690

Informa Healthcare

Access to resources Recommend Favorite